A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether KW-2246 is superior to placebo and not inferior
to immediate-release morphine for the relief of breakthrough pain in cancer patients.